Zimmer Biomet Holdings, Inc.

▲ Bull Case

• ◆ROSA OptimiZe FDA clears H1 2026, accelerating hospital conversions to 3,500 installs by FY2027; ROSA Shoulder maintains a 2–3 year head start vs. Stryker (Mako has no shoulder robot); Monogram 510(k) approved Q1 2027 — together driving a multiple re-rate to 17x FY2027E adj. EPS of $10.20, implying $190/share (+100%).
• ◆FCF of $1.54B+ in FY2026 compounds at 10%+/yr through FY2028, deleveraging the balance sheet to ~1.8x Net Debt/Adj. EBITDA by FY2028 and unlocking a sustained P/E re-rating from 12x toward 16x+ — achievable entirely without robotics upside.
• ◆Paragon 28 scales to $500M+ in revenue at 12%+ growth by FY2027, emerging as a visible second growth platform that forces analysts to decompose ZBH's blended growth rate and apply a higher multiple to the foot/ankle segment independently of the ROSA narrative.

▼ Bear Case

• ◆ROSA OptimiZe FDA clearance delayed to 2027 or beyond; US knee share loss to Mako persists at -2%/yr; CFO transition causes 2-quarter disruption — organic CC growth stays at +1–2% through FY2027, preventing operating leverage from materializing.
• ◆Leverage remains stuck near 3.0x through FY2027 (FCF disappoints or a new acquisition re-levers the balance sheet), prolonging the 'cheap for a reason' discount and delaying the multiple re-rating thesis by 12–18 months.
• ◆Multiple stays at 11x on FY2026E adj. EPS of $8.47, implying ~$90/share — a total return of -$5.00 (-5.3%) from $95, with no dividend income cushion. Severe scenario (12% probability) involves capital impairment below $75.

“Wall Street models ZBH primarily as a pure knee/hip story facing structural Mako dominance — applying a 'declining business' multiple to what management and variant investors view as a multi-modal robotics platform in early adoption. The consensus assigns near-zero value to ROSA Shoulder (the world's first robotic shoulder system, 2–3 years ahead of Stryker), ignores Paragon 28 as an independent growth platform, and treats Monogram as speculative noise. The bull variant argues that ROSA's multi-modal design (knee + hip + shoulder + THINK handheld + Monogram) is structurally unreplicable by Stryker's single-modal Mako within the investment horizon, and that each ROSA install represents 7–10 years of captive implant revenue at 69% gross margins. The bear counter is that hospital purchasing committees are already standardizing on Mako, ROSA's install base (~2,000) is below the ~3,000 flywheel threshold, and the CFO vacancy introduces guidance risk. The debate will be largely resolved by Q2–Q3 2026 organic CC acceleration data and the ROSA OptimiZe FDA 510(k) outcome.”

• ◆ROSA OptimiZe FDA 510(k) clearance (expected H1–H2 2026) — single largest near-term re-rating trigger
• ◆Q2/Q3 2026 organic CC revenue acceleration above 3% (July/October 2026 earnings)
• ◆Permanent CFO appointment with no strategy disruption (expected Q3 2026)
• ◆Paragon 28 revenue disclosure showing double-digit growth and scaling toward $450–500M by FY2027
• ◆Net Debt/Adj. EBITDA declining toward 2.3x by FY2027, enabling buyback acceleration and P/E re-rating
• ◆Monogram 510(k) filing acceptance and FDA review timeline clarity (early 2027 commercial launch guidance)

• ◆ROSA OptimiZe FDA clearance denied or delayed past 2027 — stalls hospital conversion flywheel and kills near-term ROSA adoption thesis
• ◆US knee share loss to Stryker Mako accelerates beyond modeled ~1–2%/yr, driving organic CC below 1% and making EPS growth via operating leverage mathematically impossible
• ◆CFO vacancy extends beyond Q3 2026 or permanent CFO delivers two consecutive guidance misses in first 6 months — erodes management credibility and delays institutional re-engagement
• ◆New M&A re-levers the balance sheet above 3.5x Net Debt/Adj. EBITDA, extending leverage discount and buyback constraints
• ◆Paragon 28 integration friction causes growth deceleration below 8% — removes the 'second growth platform' narrative that partially offsets legacy knee/hip erosion
• ◆Macro: hospital capex budget freezes (tariff/policy uncertainty) reduce new ROSA placements and delay robot-related implant pull-through revenue